FIG. 3.

RNase protection analysis of actinomycin D (5 μg/ml) time course RNA levels. A representative RPA of at least two independent experiments is shown for MMLV (A), HIV-1 (B), and HIV-2 (C). RPA used a constant cytoplasmic RNA amount (2.5 μg for MMLV; 0.5 μg for HIV-1 and HIV-2) and virion RNA corresponding to a constant level of RT activity (475 cpm of RT activity for MMLV; 25,000 cpm of RT activity for HIV-1 and HIV-2). Act D, actinomycin D; 2×, double input control; Y, torula yeast RNA and probe; P, undigested probe; M, RNA Century markers (Ambion; numbers adjacent to bands indicate nucleotide length of marker RNA). Levels of genomic-length RNA relative to those in untreated controls are plotted for MMLV (D), HIV-1 (E), and HIV-2 (F). MMLV gels were analyzed with NIH Image, version 1.62, and HIV gels were quantified with an Instant Imager (Packard).